Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 10/20 | 0.68 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 5/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.46 |
| ▸ | CPA1 | P15085 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGAV | P06756 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308330 | 0.88 | TPH1 (0.66) | TPH1PIN1MMEACEACE2 | |
| SCHEMBL308331 | 0.88 | TPH1 (0.66) | TPH1PIN1MMEACEACE2 | |
| SCHEMBL308166 | 0.81 | TPH1 (1.00) | TPH1 | |
| SCHEMBL308167 | 0.81 | TPH1 (1.00) | TPH1 | |
| SCHEMBL20274814 | 0.78 | TPH1 (0.61) | TPH1 | |
| SCHEMBL23921461 | 0.73 | ACE (0.58) | MMEACEACE2CPA1 | |
| SCHEMBL21777483 | 0.73 | ACE (0.58) | MMEACEACE2CPA1 | |
| SCHEMBL308641 | 0.72 | TPH1 (1.00) | TPH1 | |
| SCHEMBL308642 | 0.72 | TPH1 (1.00) | TPH1 | |
| SCHEMBL308329 | 0.69 | PTPN1 (0.48) | TPH1PIN1MMEACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | TPH1 1/4885PIN1 2004/4885MME 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.